Ondas Inc. (ONDS): Nasdaq/NYSE listing notice — Ondas Holdings receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period

Ondas Inc.

Received Nasdaq Staff Deficiency Letter on Oct 3, 2023 for bid price closing below $1.00 for 30 consecutive business days.
Has until April 1, 2024 (180 days) to regain compliance; stock must close at $1.00+ for 10 consecutive days.
If not cured, may qualify for additional 180-day period if other listing standards are met and company provides cure plan.
Company will monitor bid price and consider options including a reverse stock split; no immediate delisting effect.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Ondas Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

October 3, 2023, Ondas Holdings Inc. (the “Company”) received a letter (the “Nasdaq Staff Deficiency Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until April 1, 2024

View on SEC.gov

50 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ondas Inc. filing history →

Source: SEC EDGAR

accession 0001013762-23-002571

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.